骨髓增生异常综合症和白血病病人血清唾液酸的研究

STUDY ON SERUM SIALIC ACID IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND LEUKEMIA

检测了41例急、慢性白血病(AL,CL)和27例骨髓增生异常综合症(MDS)病人血清唾液酸(SA)浓度水平及阳性率,并与慢性再生障碍性贫血(CAA)病人比较,发现AL,CL病人的SA水平,较CAA病人及正常人显著增高,上述各组病人的阳性率分别为83.8%,60.0%,14.3%,0%,AL病人SA水平又明显高于CL并与病情变化有关,经治疗完全缓解(CR)病人血清SA水平明显降低,CR后血清SA水平与维持缓解时间有相关性。MDS病人血清SA明显高于正常人而低于AL病人,MDS及其亚型RA+RAS组、RAEB+RAEB-t+CMML组的阳性率分子为33.3%,20.0%,50.0%,结果显示,血清SA升高可能与疾病发生发展有关。血清SA的检测对疾病诊断与鉴别诊断,判断病情、疗效及预后判断均具有一定的临床价值。

Serum sialic acid (SA) contents in 41 patients with leukemia (AL,CL), 27 with myelodysplastic syndrome (MDS) and 14 with chronic aplastic anemia (CAA) were measured. The results showed that the serum SA level was significantly higher in pa- tients with AL, CL and MDS than in the normal controls (P<0.01), but there was no marked difference between patients with CAA and the controls in SA contents. (P>0.05). The positive rates among the patients with AL, CL, MDS, CAA and the controls were 83.8%, 60.0%, 33.3%, 14.3% and 0% respectively. The serum SA levels in the AL patients were much higher than those in the CL and MDS patients, and changed with the patients' condition. Serum SA levels in patients in complete remission (CR) after treatment dropped remarkably, and were correlated with the duration of CR. The above suggests that the serum SA level was related to the occurrence and the progress of the disease. An assay of the serum SA level is, therefore, helpful in the ear- ly disgnosis, observation and evaluation of the prognosis of the disease.